Dopamine Uptake through the Norepinephrine Transporter in Brain Regions with Low Levels of the Dopamine Transporter: Evidence from Knock-Out Mouse Lines

By José A. Morón, A. Brockington, R. Wise, B. Rocha, B. Hope. Journal of Neuroscience, 2002

687 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e32bb1abc682dc7490aea0d6039136bf1edd0139

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Samuel R. Chamberlain
2. Barbara J. Sahakian
3. Cameron S. Carter
4. Michael J. Minzenberg
5. Charles R. Yang
6. Trevor W. Robbins
7. David J. Nutt
8. Jeremy K. Seamans

In Molecular Biology

1. Cameron S. Carter
2. Michael J. Minzenberg
3. Samuel R. Chamberlain
4. Barbara J. Sahakian
5. Trevor W. Robbins
6. David J. Nutt
7. Jeremy K. Seamans
8. Charles R. Yang

Citations in the corpus

• The principal features and mechanisms of dopamine modulation in the prefrontal cortex. (2004, background): “Unlike striatum, a significant portion of PFC DA uptake is mediated by the norepinephrine transporter (NET) and catabolized enzymatically by COMT, more so than by MAO (Cass and Gerhardt, 1995; Wayment et al., 2001; Moron et al., 2002; Bymaster et al., 2002).”
• Modafinil: A Review of Neurochemical Actions and Effects on Cognition (2008, background): “There remains the possibility that the enhanced DA results from competition with NE for binding to the NET, which plays an important role in terminating DA action in the cortex (Carboni et al, 1990; Moron et al, 2002).”
• Amphetamine, past and present – a pharmacological and clinical perspective (2013, background): “The density of DAT sites on PFC dopaminergic neurones is very low (Hitri et al., 1991), and as a consequence, most dopamine that is released is sequestered via NET into noradrenergic neurones (Mazei et al., 2002; Morón et al., 2002; Stahl, 2003).”
• The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. (2009, neutral): “of dopamine transporters in this region (Gogos et al., 1998; Lewis et al., 2001; Mazei et al., 2002; Moron et al., 2002).”
• The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. (2011, background): “Dopamine has a higher ffinity for NAT than for DAT, and thus, it is the NA system (via NAT) hat controls the termination of DA transmission in the frontal ortex (73).”